NEW YORK (GenomeWeb News) – Cancer diagnostics firm VolitionRx has raised $595,000 toward a targeted $1.5 million round, it said in a document filed with the US Securities and Exchange Commission.
In an e-mail to GenomeWeb Daily News, a company spokesperson said the funding will go toward ongoing trials for its NuQ technology, including clinical trials announced late last month with Hvidovre Hospital in Denmark for colorectal cancer.
Investors in the round consisted of individual investors. The company has raised a total of $1.5 million in 2013 and about $6.0 million since its founding in late 2010.
In May 2012, the Singapore-based firm raised $1.2 million to fund clinical trials for its first NuQ test kits, which are blood-based diagnostic tests based on VolitionRx’s Nucleosomics technology. The technology detects and measures nucleosomes in the bloodstream.